CERC-301: Ph II Clin301-203 data

Last November, Cerecor reported top-line data from the double-blind, U.S. Phase II Clin301-203 trial in 115 MDD patients showing that adjunctive treatment with 12 and 20 mg oral CERC-301 on days 0 and 7 each missed the primary endpoint of improving Bech-6 score averaged over days 2 and 4 post-treatment vs. placebo (Period 1: 2.5 and 4.11 points, respectively, vs. 3.82 points; Period 2: 1.64 and 3.38 points, respectively, vs. 2.86 points). The trial consisted of 2 sequential 1-week periods. Placebo non-responders in Period 1 were re-randomized to CERC-301 or placebo in Period 2...